NCT05021666View on ClinicalTrials.gov

A Phase 1, Double-blind, Randomized, Placebo-controlled, Single- and Multiple-dose Escalating Study

PHASE1CompletedINTERVENTIONAL

Enrollment

82

Participants

Timeline

Start Date

July 29, 2020

Primary Completion Date

May 18, 2022

Study Completion Date

August 12, 2022

Conditions

Healthy Subjects

Interventions

DRUG

Placebo

matching placebo

DRUG

PB 718

dose in the next group will be determined following a review of data from the previous group

Trial Locations (1)

32117

Covance Clinical Research Unit Inc., Daytona Beach

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Covance

INDUSTRY

lead

PegBio Co., Ltd.

OTHER